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Percutaneous PFO closure with Amplatzer PFO occluder:
predictors of residual shunts at 6 months follow-up
Abstract
OBJECTIVE: The objective of this study was to assess predictors of residual shunts after percutaneous
patent foramen ovale (PFO) closure with Amplatzer PFO occluder (AGA Medical Corporation, Golden
Valley, MN, USA). METHODS: All percutaneous PFO closures, using Amplatzer PFO occluder
performed at a tertiary center between May 2002 and August 2006, were reviewed. Follow-up,
including saline contrast transesophageal echocardiography, was performed in all patients 6 months
after the intervention. PATIENTS: A total of 135 procedures were performed. Mean age of the patients
was 51 years. The indication for PFO closure was an ischemic cerebrovascular event in 92%,
paradoxical systemic embolism in 4%, and a diving accident in 4%. Recurrent events prior to PFO
closure were noted in 34%. A concomitant atrial septal aneurysm was present in 61%. RESULTS: At 6
months follow-up, a residual shunt was detected in 26 patients (19%). Residual shunts were more
common in patients with an atrial septal aneurysm (27 vs. 8%, P= .01) and in patients treated with a
35-mm compared with a 25-mm device (39 vs. 15%, P= .01). A concomitant atrial septal aneurysm
remained independently associated with residual shunts when controlled for body mass index, gender,
age, atrial dimensions, and presence of a Chiari network (odds ratio 4.1, 95% confidence intervals
1.1-15.0). CONCLUSION: The presence of atrial septal aneurysms in patients undergoing percutaneous
PFO closure with an Amplatzer PFO occluder significantly increases the rate of residual shunts at 6
months follow-up, even if 35-mm devices are used.
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Abstract 
Objectives: To assess predictors of residual shunts after percutaneous PFO-
closure with Amplatzer PFO occluder. 
Methods: All percutaneous PFO closures, using Amplatzer PFO occluder 
performed at a tertiary centre between May 2002 and August 2006 were 
reviewed. Follow-up, including saline contrast transesophageal 
echocardiography was performed in all patients six months after the 
intervention. 
Patients: A total of 135 procedures were performed. Mean age of the patients 
was 51 years. The indication for PFO closure was an ischemic 
cerebrovascular event in 92%, paradoxical systemic embolism in 4% and a 
diving accident in 4%. Recurrent events prior to PFO closure were noted in 
34%. A concomitant atrial septal aneurysm was present in 61%.  
Results: At 6 months follow-up a residual shunt was detected in 26 patients 
(19%). Residual shunts were more common in patients with an atrial septal 
aneurysm (27% versus 8%, p = 0.01) and in patients treated with a 35mm 
compared to a 25mm device (39% versus 15%, p = 0.01). A concomitant atrial 
septal aneurysm remained independently associated with residual shunts 
when controlled for body mass index, gender, age, atrial dimensions and 
presence of a Chiari network (odds ratio 4.1, 95% confidence intervals 1.1-
15.0). 
Conclusion: The presence of atrial septal aneurysms in patients undergoing 
percutaneous PFO closure with an Amplatzer PFO occluder significantly 
increases the rate of residual shunts at six months follow-up, even if 35mm 
devices are used. 
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Introduction 
In patients with stroke of unknown etiology (cryptogenic stroke) and a patent 
foramen ovale (PFO), percutaneous closure has been advocated as an 
alternative strategy to lifelong antithrombotic therapy, particularly in the 
presence of associated atrial septal aneurysms and in young individuals. 
While several types of occluders for PFO device closure are available in the 
market, the Amplatzer PFO occluder (AGA Medical Corporation, Golden 
Valley, Minnesota) currently is still the most widely used. One limitation of any 
percutaneous device closure is the possible persistence of a residual shunt, 
which may occur in up to 29% [1]. An association between residual shunts 
and recurrent ischemic events has been demonstrated [2,3,4,5] but little is 
known about predictors of residual shunts after percutaneous PFO-closure. 
 
Aim of the study 
We sought to identify predictors of a residual shunt six months after 
percutaneous PFO closure with the Amplatzer PFO occluder. 
 
Methods 
Patient population: All patients, referred for interventional closure of a PFO 
at a single tertiary centre between May 2002 and August 2006, were included. 
All patients were assessed by a standardized protocol including transthoracic 
(TTE) and transesophageal echocardiography (TEE) before device closure 
and 6 months thereafter. The echocardiographic studies included the injection 
of agitated saline contrast into an antecubital vein to demonstrate a right to 
left shunt, either at rest or following the Valsalva manoeuvre. It was 
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considered positive if bubble contrast in the left atrium was noted within the 
first 3 cardiac cycles after their appearance in the right atrium. An atrial septal 
aneurysm was defined as a maximum deflection of the atrial septum of at 
least 15mm on M-Mode recording perpetual to the atrial septum [6]. The 
devices used were 25mm- and 35mm-Amplatzer PFO occluders at the 
discretion of the operator. The procedure was performed under local 
anaesthesia and fluoroscopic control, without periprocedural 
echocardiography. All patients were loaded with Aspirin prior to the procedure 
and oral double antiplatelet therapy with Aspirin and Clopidogrel was 
maintained for 3 months, followed by Aspirin only for an additional 3 months. 
Patients with a history of previous stroke or TIA were kept on treatment with 
low dose Aspirin thereafter, irrespective of the presence of a residual shunt. A 
chest radiograph was performed routinely the day after the procedure. All 
patients had an outpatient follow up visit after six months, including a 
comprehensive transthoracic and transesophageal echocardiography with 
saline contrast injection. 
Outcomes: The main outcome measure was the presence of a residual 
interatrial shunt at six months follow-up, detected by TTE or TEE after 
intravenous injection of agitated saline contrast. Secondary outcome 
measures were recurrence of ischemic events, periprocedural complications 
and complications during follow-up. 
Statistical analysis: Continuous variables were expressed as means (SD), 
and differences among the groups of patients were tested with Student’s t-
test. Categorical data were presented as actual numbers and percentages, 
and a Chi-squared test was used to test for differences among the groups. 
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Patient and procedural characteristics (indication for PFO closure, presence 
of an atrial septal aneurysm, size of the device used, gender, age at 
implantation, presence of a Chiari network in the right atrium, atrial size and 
body mass index) were tested as predictors for residual shunts. When a 
significant predictor for a residual shunt was identified in the univariate 
analysis it was further evaluated by means of a multiple logistic regression. 
Statistical significance was assumed with a two-sided p value < 0.05. 
 
Results 
Patients and procedures: A total of 135 consecutive procedures were 
performed. The mean age of the patients was 51 (+/- 12) years with a range 
of 21 to 75 years. Fifty-eight percent of patients were male and 36% were 
older than 55 years. Demographic and baseline characteristics are 
summarized in table 1.  
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Table 1: Baseline characteristics, atrial septal anatomy and indication for 
PFO closure 
 
Characteristic patients (n = 135) 
Mean age (+/- SD) (years) 51 (+/- 12) 
 Age > 55 years (%) 48 (36) 
Male sex (%) 78 (58) 
Cardiovascular risk factors  
 Diabetes mellitus (%) 3 (2) 
 History of dyslipidemia (%) 53 (39) 
 History of hypertension (%) 37 (27) 
 Current smoking (%) 30 (22) 
 Positive family history (%) 24 (18) 
Body mass index (+/- SD) (kg/m2) 25.4 (+/- 4) 
Isolated PFO (%) 53 (39) 
Concomitant atrial septal aneurysm (%) 82 (61) 
Reason for PFO closure  
 Stroke (%) 93 (69) 
 Transient ischemic attack (%) 31 (23) 
 Stroke or TIA (%) 124 (92) 
 Paradoxical peripheral embolism (%) 6 (4) 
 Diving accident (%) 5 (4) 
 Recurrent embolic events (%) 46 (34) 
 
The index event for closure of the PFO was a transient ischemic attack in 
23%, an ischemic stroke in 69%, paradoxical peripheral embolism in 4% and 
a diving accident in 4% of patients. Thirty four percent of patients had 
recurrent ischemic events prior to the intervention. Thirty-nine percent of 
patients had an isolated PFO, whereas in 61% of patients a concomitant atrial 
septal aneurysm was present. There was no difference between patients with 
and without recurrent embolic events regarding the presence of an atrial 
septal aneurysm (57% and 63% respectively, p-value = 0.58). 
To choose the most appropriate device size, transthoracic and 
transesophageal echocardiograms were carefully reviewed before every 
procedure. None of the patients included in this series had a multifenestrated 
ASA or multiple defects within the interatrial septum. The decision, whether to 
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use a 25mm or a 35mm device was based on a qualitative assessment of the 
size of the ASA and the size of the PFO on preprocedural TEE. No formal 
sizing procedure was performed. A 35mm Amplatzer PFO occluder was used 
in a total of 23 cases (17%), 21 of whom had a concomitant atrial septal 
aneurysm (25.6% of all patients with atrial septal aneurysms). In 19 patients 
the 35mm device was chosen based on findings on preprocedural TEE and in 
four patients after the smaller device had either prolapsed or its position had 
appeared unstable during the procedure itself. 
Outcomes: Echocardiography at six months follow up detected a residual 
interatrial shunt in 26 patients (19.3%). In a semiquantitative manner, 10 out 
of those 26 shunts (38%) were considered to be significant (right to left shunt 
with more than 20 bubbles counted in the left atrium, either spontaneously or 
after the Valsalva manoeuvre). The residual shunt was localized at the 
circumference of the device in 12 patients and across the discs of the device 
in 6 patients. In eight patients with a persistent right to left shunt on saline 
contrast echocardiography, the localization of the shunt remained 
undetermined, including 3 patients, in whom a residual shunt was only 
detected on transthoracic study after release of the Valsalva manoeuvre. In 
none of the patients with a residual shunt a separate defect within the 
interatrial septum was detected on TEE.  
Comparing the groups with and without residual shunts there were no 
differences in baseline characteristics such as gender, symptoms, age, or 
body mass index. With respect to anatomical variables, no difference was 
found regarding atrial dimensions and the presence of a Chiari network (see 
table 2).  
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Isolated PFO  4 / 53 8 
PFO/ atrial septal aneurysm 22 / 82 27 0.01 
25mm PFO-occluder 17 / 112 15 
35mm PFO-occluder 9 / 23 39 0.01 
Male patients 16 / 78 21 
Female patients 10 / 57 18 0.84 
Age > 55 years 12 / 48 25 
Age <55 years 14 / 87 16 0.3 
BMI > 25 8 / 53 15 
BMI < 25 18 / 82 22 0.4 
RA long axis > 50mm 6 / 30 20 
RA long axis < 50mm 20 / 105 19 0.9 
Chiari network present 7 / 30 23 
Chiari network not present 19 / 105 18 0.7 
 
A residual shunt was significantly more prevalent in patients with a 
concomitant atrial septal aneurysm, as compared to those patients with an 
isolated PFO (27% versus 8%, p = 0.01). A residual shunt was also more 
common in patients treated with a 35mm Amplatzer PFO occluder, compared 
to those having received a 25mm device (39% versus 15%, p = 0.01). Of all 
cases in whom a 35mm occluder had been used, only two patients had had 
an isolated PFO without atrial septal aneurysm. Both patients had a large 
PFO at baseline and neither of them had a residual shunt at follow-up. When 
tested in a logistic regression model, including presence of an atrial septal 
aneurysm, body mass index, gender, age at implantation, atrial dimensions, 
and presence of a Chiari network, only the presence of an atrial septal 
aneurysm was significantly associated with a residual shunt at follow-up (odds 
ratio 4.1, 95% confidence intervals 1.1-15.0). There remained a trend towards 
more residual shunts (odds ratio 3.2, 95% confidence intervals 0.9-11.6, p = 
0.075) even when controlled for the size of the device used. 
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A subset of 12 patients (46%) with residual shunts underwent repeat 
transesophageal echocardiography 12 months after implantation. This 
investigation demonstrated the disappearance of the residual shunts in two 
out of nine patients (22%) with 35mm occluder and in 1 out of 17 patients with 
25mm occluder. Both shunts  
 
One patient with a large residual 6 months after implantation of a 35mm 
device underwent a second procedure with implantation of a 25mm device, 
which completely sealed the residual defect. 
 
Secondary endpoints: Two patients (1.5%) had recurrent ischemic events 
during follow up. The first patient had been treated with a 35mm PFO device 
and a residual shunt was detected at follow up. He suffered a diving accident, 
without permanent sequelae. The second patient had been treated with a 
25mm occluder and had no detectable residual shunt at follow up. He suffered 
a transient ischemic attack without permanent sequelae.  
Periinterventional complications occurred infrequently. There was one device 
embolization during the procedure in a patient with a large atrial septal 
aneurysm. The device was removed percutaneously and the PFO was 
successfully closed with a larger device during the same procedure. Vascular 
access complications were observed in 2.2% of cases. These included two 
pseudo-aneurysms, treated with thrombin injection and one arterio-venous 
fistula, which spontaneously closed a few weeks later. In four patients (3%) 
transient atrial fibrillation at the time of device implantation was recognized. All 
those episodes terminated spontaneously after a maximum of 12 hours. At six 
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months follow-up one patient was incidentally found to have a thrombus on 
the left atrial disc and in one patient, the ECG showed asymptomatic atrial 
fibrillation. Both patients were treated with oral anticoagulation and both 




The rate of residual interatrial shunts after PFO closure with Amplatzer 
devices has been investigated in several studies 
[1,2,3,5,7,8,9,10,11,12,13,14,15,16,17]. However, direct comparison of the 
results of these studies is difficult. Although different types of devices have 
been used in several series, a differentiation of shunt rates for different device 
types was not always reported. In addition the methods of follow up were not 
uniform regarding time and modality of follow up. For example, not in all 
series a TEE with saline contrast was routinely performed in follow up. 
Comparable larger series with similar follow up modalities, described rates of 
residual shunts at 6 months follow up of 8-19%. [2,3,5,10,14,17]. 
In our patient group, we found a high rate of 19% residual shunts at 6 months. 
This might partly be explained by the high percentage of concomitant atrial 
septal aneurysms in our series, reflecting the restrictive referral policy at our 
institution. Therefore there may have been a bias towards more residual 
shunts as mainly patients with large atrial septal aneurysms were referred for 
PFO closure.  
Only few series investigated predictors of residual shunts at follow up [3,5,17]. 
The higher rate of residual shunts in the presence of an atrial septal aneurysm 
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could be demonstrated only in some series [5,17]. Zajarias et al [17] 
described a residual shunt at 6 months follow up after percutaneous PFO 
closure with Amplatzer devices in 7/7 patients in the presence of an atrial 
septal aneurysm. Wahl et al [5] clearly demonstrated an association of a 
residual shunt with larger devices. This finding could not be demonstrated in 
the series of Zajarias [17]. In our series a 35mm occluder was used almost 
exclusively in patients with atrial septal aneurysms and thus, the size of the 
device could not be demonstrated to be an independent predictor of residual 
shunts. 
Several factors may play a role for the fact, that residual shunts were more 
prevalent in patients with an atrial septal aneurysm and especially in those in 
whom a 35mm occluder was used. First, even the 35mm occluder may be too 
small to fully cover a large atrial septal aneurysm as is shown in figure 1.  
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Figure 1: Fluoroscopic views after implantation of an Amplatzer 35mm 
occluder in a patient with PFO and large atrial septal aneurysm. Panel A 
depicts the occluder at the time of implantation (large arrow) showing a good 
hold on the secundum atrial septum (small arrow). Panel B shows the 
situation 10 months later, after a large residual shunt was detected on 
echocardiography. The device has slipped off the septum secundum (arrow).  
 
 
Second, in patients in whom a 35mm occluder is needed, the larger device 
may unfavourably alter the atrial septal geometry and therefore prevent 
proper alignment of the occluder to the atrial septum (see figure 2).  
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Figure 2: Incomplete apposition of an Amplatzer 35 mm PFO occluder (large 
arrow) to the atrial septum (small arrow) before (panel A) and after (panel B) 




Third the larger surface of the 35mm device might delay endothelialization 
[14]. The latter hypothesis would be supported by the finding of 
disappearance of a residual shunt in some patients with large devices after 
one year follow up. 
To overcome the problem of frequent residual shunts in patients with large 
atrial septal aneurysms the use of other devices, for example Amplatzer ASD 
occluder, or the use of alternative implantation techniques, for example 
through a prior transseptal puncture, might be considered. Compared to the 
Amplatzer PFO occluder with its narrow waist, the Amplatzer ASD occluder is 
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The main limitation of our study is the small size of our patient group and 
therefore the small number of patients with residual shunts. To what extent 
the rate of residual shunts decreases after longer follow up has not been 
investigated routinely.  
Due to the short follow up period we could not determine, whether these 




The presence of atrial septal aneurysms in patients undergoing percutaneous 
PFO closure with an Amplatzer PFO occluder significantly increases the rate 
of residual shunts at six months follow-up, even if 35mm devices are used.
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